According to Huabang Health's announcement, Chongqing Huabang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for cazosangdopa extended-release tablets approved by the State Drug Administration. The drug is a class of 4 chemicals. The specifications are carbidopa 50 mg and levodopa 200 mg. It is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs. Indications include primary Parkinson's disease, etc., which will enrich the company's product pipeline in the field of Parkinson's disease treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.